Novartis inks $1B-plus biobucks deal with Flagship's Generate

Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop protein therapeutics across multiple indications.

The companies did not disclose specifics about potential disease areas, referring only to the pact as a “multi-target collaboration” in a Sept. 24 release.